Influence of stage discrepancy on outcome in. in patients treated with radical cystectomy.

Size: px
Start display at page:

Download "Influence of stage discrepancy on outcome in. in patients treated with radical cystectomy."

Transcription

1 Tumori, 96: , 2010 Influence of stage discrepancy on outcome in patients treated with radical cystectomy Ja Hyeon Ku 1, Kyung Chul Moon 2, Cheol Kwak 1, and Hyeon Hoe Kim 1 1 Department of Urology, and 2 Department of Pathology, Seoul National University College of Medicine, Seoul, Korea ABSTRACT Aims and background. To evaluate the influence of stage discrepancy on clinical outcome in patients with bladder cancer who have undergone radical cystectomy. Methods and study design. We reviewed the records of 155 patients who had undergone radical cystectomy. Of the 155 patients (128 males, 27 females), 68 had clinical nonmuscle invasive disease and 87 had muscle invasive disease. Follow-up ranged from to months (median, 34.3). Results. There was no significant difference in overall survival according to clinical T stage (P = 83). However, the actuarial overall survival rate of the pathological muscle invasive disease group was significantly less than that in the pathological nonmuscle invasive disease group (P <01). Multivariate analysis with the Cox regression model revealed that lymphovascular invasion (P = 01, relative risk [RR] = 2.463) and pathological T stage (P = 03, RR = 3.148) were strongly associated with overall survival. There was no difference in cancer-specific survival according to clinical T stage (P = 55). However, cancer-specific survival rate of the pathological muscle invasive disease group was significantly less than that in the pathological nonmuscle invasive disease group (P <01). Multivariate Cox proportional hazards model analysis showed that lymphovascular invasion (P = 01, RR = 2.545) and pathological T stage (P = 02, RR = 3.823) were independent predictors of cancerspecific survival. Conclusions. Our findings indicate that clinical stage determined by transurethral resection is not predictive of clinical outcome after radical cystectomy in patients with bladder cancer. Free full text available at Introduction Accurate clinical staging is important, and the mainstay of clinical staging for muscle invasive bladder cancer (MIBC) is pathologic examination of the transurethral resection (TUR) specimen. The pathological evaluation of tumor stage provided by TUR is critical, since the information directs therapy and influences prognosis. However, the clinical stage of disease may be discordant with the final pathologic stage determined after radical cystectomy by incomplete resection of the tumor, and a single TUR leaves residual disease in a significant number of patients. The percentage of positive histologic findings at the second TUR has been reported to range from 15% to 75% 1,2. In addition, it has been reported that more than 30% of patients with T1 transitional cell carcinoma of the bladder who have undergone radical cystectomy may be under-staged, which reflects limitations in the current staging modalities 3-6. Furthermore, potential impact of stage discrepancy on prognosis has yet to be evaluated in patients treated with radical cystectomy. To evaluate the impact of the stage discrepancy on clinical outcome, we performed a retrospective analysis in patients with bladder cancer who had undergone radical cystectomy. Key words: bladder neoplasm, cystectomy, recurrence, stage, survival. Correspondence to: Hyeon Hoe Kim, MD, PhD, Department of Urology, Seoul National University Hospital, 28, Yongon Dong, Jongno Ku, Seoul, , Korea. Tel ; fax ; hhkim@snu.ac.kr Received May 14, 2009; accepted October 16, 2009.

2 700 JH KU, KC MOON, C KWAK, HH KIM Material and methods Approval of the study was obtained from the Institutional Review Board. We retrospectively reviewed the records of 162 consecutive patients with transitional cell carcinoma of the bladder who had undergone radical cystectomy at our institution between January 1991 and December Before radical cystectomy, TUR was performed in all patients for diagnostic and therapeutic purposes by staff urologic oncologists at our institution. The TUR were fully standardized; the bladder was thoroughly examined endoscopically, and the location, number and size of tumors were indentified. TUR of all visible tumors was then performed down to the lamina propria, and several deep muscular samples were also taken from the tumor base. No second resection was performed. Pathological data were reviewed and clinical staging was assigned based on an interpretation of the initial TUR specimens. In the present study, clinical staging was assigned based on an interpretation of the TUR specimens, and we used the term pathologic stage based on an interpretation of radical cystectomy specimens. We then compared the clinical and final pathological stage after radical cystectomy. Patients who received either preoperative or postoperative chemotherapy were excluded. Thus, 155 patients were enrolled in the study. Clinical information was collected for all patients, including preoperative demographics and indication for radical cystectomy. The mean age at radical cystectomy was 6 years (range, 32-84). The indications for radical cystectomy in cases of nonmuscle invasive bladder cancer (NMIBC) were disease refractory to intravesical therapy and tumor characteristics associated with a high risk of recurrence or progression. Of the 155 patients (128 males, 27 females) studied, 68 had clinical NMIBC and 87 had MIBC. The mean number of previous TUR was 2.0 (range, 0-25), and 32 patients (2%) had a previous history of intravesical instillation of bacillus Calmette-Guerin (BCG). Follow-up ranged from to months (median, 34.3). Evaluation included the histopathological result of the radical cystectomy and clinical outcome. All grading was performed using the World Health Organization (WHO) consensus classification of urothelial neoplasms 7, whereas stage was determined according to the WHO/International Society of Urologic Pathology (ISUP) 1998 classification system 8. Pathologic vascular invasion was defined as tumor present in vessels with a vascular wall and red blood cells in the lumen. Only when the tumor had invaded vessels with a definite endothelial lining was it considered lymphatic invasion. Perineural invasion was defined as tumor invading the perineural sheath or endoneurium. To evaluate which risk factor was most highly associated with the pathological MIBC in radical cystectomy specimens with respect to clinical and histologic variables, odds ratios and the P values for trend were estimated by multivariate logistic regression analysis. Clinical characteristics were entered into the model individually as independent variables. The associations between these parameters and the pathological MIBC were described using maximum likelihood estimates of odds ratios and 95% confidence intervals (CI) based on the logistic regression model. CI were based on the standard errors of the coefficients and a normal approximation. Outcomes were measured by time to overall survival and cancer-specific survival. Time to overall survival was calculated as the time from cystectomy to the date of death for any cause or until last follow-up if the patient had not died. Time to cancer-specific survival was calculated as the time from cystectomy to the date of death attributable to bladder cancer or until last followup if the patient had not died of bladder cancer. Survival analyses were conducted according to the Kaplan- Meier method, and survival characteristics were compared using logrank tests 9. Multivariate analysis by Cox s proportional hazards model was used to determine the contribution of several clinicopathologic factors to the survival rates of patients 10. The statistical software package SPSS 13.0 (SPSS, Inc., Chicago, IL, USA) was used for all statistical analyses. All calculated P values were 2- sided, and a P value of <5 was considered statistically significant. Results Table 1 compares clinical parameters according to the clinical stage determined by TUR. No significant difference in terms of clinical stage was observed according to age, sex, American Society of Anesthesiologists (ASA) score, number of previous TUR, or the incidence of perineural invasion in pathologic specimens. However, patients with clinical NMIBC had more intravesical BCG instillation (P = 47), received more orthotopic bladder substitute (P = 17), had higher incidence of lymphovascular invasion (P = 20), and had a lower pathological stage (P = 05). The comparison of clinical and pathologic stages is shown in Table 2. Clinical and pathologic stages were identical in 27.7% (43 of 155) of patients. Pathologic down-staging and up-staging occurred in 2% (31 of 155) and 52.3% (81 of 155), respectively. For predicting pathological MIBC, sensitivity and specificity of clinical stage were 64.7% (66 of 102) and 6% (32 of 53), respectively. To evaluate the influence of clinical and histologic parameters on pathological MIBC, the parameters were included in the univariate logistic model. The univariate logistic regression analysis indicated that history of BCG instillation, lymphovascular invasion and clinical T

3 INFLUENCE OF STAGE DISCREPANCY IN BLADDER CANCER 701 Table 1 - Clinical and pathological characteristics Tumor stage at TUR 1 Variable P 2 Age (yr) 09 <60 26 (38.2) 39 (44.8) (61.8) 48 (55.2) Sex 22 Male 55 (80.9) 73 (83.9) Female 13 (19.1) 14 (16.1) ASA score (33.8) 27 (3) (66.2) 60 (69.0) No. of previous TUR (57.4) 63 (72.4) 1 29 (42.6) 24 (27.6) History of BCG instillation 47 Absent 49 (72.1) 74 (85.1) Present 19 (27.9) 13 (14.9) Procedure 17 Conduit 46 (67.6) 73 (83.9) Neobladder 22 (32.4) 14 (16.1) Lymphovascular invasion 20 Absent 52 (76.5) 51 (58.6) Present 16 (23.5) 36 (41.4) Perineural invasion Absent 64 (94.1) 78 (89.7) Present 4 (5.9) 9 (10.3) Pathologic stage 05 pt0 7 (10.3) 3 (3.4) CIS 1 (1.5) 5 (5.7) pta 4 (5.9) 6 (6.9) pt1 20 (29.4) 7 (8.0) pt2 15 (22.1) 24 (27.6) pt3 16 (23.5) 35 (4) pt4 5 (7.4) 7 (8.0) ASA, American Society of Anesthesiologists; BCG, bacillus Calmette- Guerin; TUR, transurethral resection. 1 Data presented are number and percentage of patients. 2 Chi-square test. Table 2 - Comparison of bladder tumor stage after initial transurethral resection (TUR) and subsequent radical cystectomy Clinical stage at TUR cta ct1 ct2 Pathologic stage at radical cystectomy pt0 2 (2) 5 (8.6) 3 (3.4) PTis 0 () 1 (1.7) 5 (5.7) PTa 2 (2) 2 (3.4) 6 (6.9) PT1 3 (3) 17 (29.3) 7 (8.0) PT2 2 (2) 13 (22.4) 24 (27.6) PT3 1 (1) 15 (25.9) 35 (4) pt4 0 () 5 (8.6) 7 (8.0) Stage discrepancy Down-staged 2 (2) 8 (13.8) 21 (24.1) Same staged 2 (2) 17 (29.3) 24 (27.6) Up-staged 6 (6) 33 (56.9) 42 (43.8) Number and percent of cases. stage were possible risk factors for pathological MIBC. These variables were selected for the multivariate logistic model to determine their association with pathological MIBC. In the multivariate model used, all three variables were independent risk factors: no history of BCG instillation was associated with a increased likelihood of pathological MIBC (odds ratio, 3.16; 95% CI, 1.32 to 7.58; P = 10); patients with lymphovascular invasion had a 4.3-fold higher risk (odds ratio, 4.29; 95% CI, 1.72 to 19; P = 02) than those without lymphovascular invasion; clinical T stage was associated with pathological MIBC (odds ratio, 2.10; 95% CI, 0 to 4.38; P = 49). The results are shown in Table 3. During the follow-up, 61 patients (39.4%) died, and median overall survival was 34.3 months (95% CI, 4.0 to 139.5). there was no significant difference in overall survival according to clinical T stage (Figure 1A, P = 83, logrank test). However, the actuarial overall survival rate of the pathological MIBC group was significantly less than that of the pathological NMIBC group (Figure 1B, P <01, logrank test). In addition, multivariate analysis with the Cox regression model revealed that lymphovas- Table 3 - Risk factors for pathological muscle invasive disease in patients who underwent radical cystectomy OR (95% CI) P Adjusted OR P (95% CI) Age (yr) < ( ) 45 Sex Male 00 Female 48 ( ) ASA score ( ) No. of previous TUR (73-84) 83 History of BCG instillation Absent ( ) < ( ) 10 Present Procedure Conduit 00 Neobladder 85 (26-39) 63 Lymphovascular invasion Absent Present ( ) < ( ) 02 Perineural invasion Absent 00 Present ( ) 54 Clinical T stage ( ) ( ) 49 ASA, American Society of Anesthesiologists; BCG, bacillus Calmette- Guerin; CI, confidence interval; OR, odds ratio; TUR, transurethral resection.

4 702 JH KU, KC MOON, C KWAK, HH KIM cular invasion (P = 01, relative risk [RR] = 2.463) and pathological T stage (P = 03, RR = 3.148) were strongly associated with overall survival, regardless of age, sex, ASA score, number of previous TUR, history of intravesical BCG instillation, type of procedure, perineural invasion or clinical T stage (not shown). There was no difference in cancer-specific survival according to clinical T stage determined by TUR (Figure 1C, P = 55, logrank test). However, cancer-specific survival rate of the pathological MIBC group was significantly less than that in the pathological NMIBC group (Figure 1D, P <01, logrank test). Multivariate Cox proportional hazards model analysis showed that lymphovascular invasion (P = 01, RR = 2.545) and pathological T stage (P = 02, RR = 3.823) were independent predictors of cancer-specific survival (not shown). Discussion In most cases, therapeutic decisions concerning bladder tumors are based on the results of an initial TUR of the bladder tumor. If adequately performed, TUR allows precise differentiation between NMIBC and MIBC. However, there are many factors that confound the adequacy of resection, which include the multiplicity of disease, the capability and perseverance of the resectionist, the qualities of specimens provided and the pathological analysis 2. The etiology of stage disparity has another possible sources, i.e., delay in the interval from TUR to radical cystectomy 11. Furthermore, in the case of TUR specimens, the pathologic material given for examination may be limited by the size, depth, quality, or location of the tumor 12. A B Overall survival Overall survival P = 83, log-rank test P <01, log-rank test C D Cancer specific survival Cancer specific survival P = 55, log-rank test P <01, log-rank test Figure 1 - A) Overall survival by clinical T stage determined by transurethral resection specimens (P = 83, logrank test). B) Overall survival by pathological T stage determined by radical cystectomy (P <01, logrank test). C) Cancer-specific survival by clinical T stage determined by transurethral resection specimens (P = 55, logrank test). D) Cancer-specific survival by pathological T stage determined by radical cystectomy (P <01, logrank test).

5 INFLUENCE OF STAGE DISCREPANCY IN BLADDER CANCER 703 The inaccuracies of a single TUR have been documented as inconsistencies between the clinical and pathologic stages. Soloway et al. 5 reported that the overall clinical staging error was 61.5%, with 41.5% of the cancers under-staged. Richie et al. 13 compared clinical and pathologic stages and found that 26% of patients studied had been up-staged and 40% under-staged 13. Herr 2 reported that 29% with NMIBC was up-staged to an MIBC on repeated resection. Freeman et al. 6 indicated that in patients with clinical NMIBC, pathologic upstaging to MIBC or metastatic tumor occurred in 34% of patients. Furthermore, whereas less than 20% of patients with Ta tumors were under-staged 6, up to 40% of patients with T1 tumors were up-staged to muscle invasion 3,6,14. Conceptually, a second TUR would allow more accurate staging by excluding patients whose disease stage is revised upward by repeated resection 15,16. However, since no second resection was performed in our study, clinical stage may have been under-staged, especially in T1 disease. In accordance with previous reports 6,17, we found that a number of patients with high-risk clinical NMIBC had muscle invasion in their cystectomy specimen. Thus, discrepancy between clinical and pathologic stage is common in patients who undergo radical cystectomy. These findings may support the need to consider early cystectomy in some of patients with high-risk clinical NMIBC. Furthermore, our findings indicate that clinical stage determined by TUR is not predictive of clinical outcome after radical cystectomy in patients with bladder cancer. Finally, the prognostic implications of pathologic features such as vascular invasion, lymphatic invasion, and perineural invasion have been drawing attention. Controversy still surrounds the prognostic implications of vascular, lymphatic, and perineural invasion in bladder cancer. Some investigators reported that these may be useful prognostic factors for bladder cancer 18,19. However, others have suggested that these pathologic features were not associated with patient survival 20 or not independent prognostic factors regarding survival 21,22. In the present study, lymphovascular invasion was an independent prognostic factor regarding overall survival and cancer-specific survival of patients with bladder cancer after curative radical cystectomy. Although further study is needed to verify these findings, our results suggest that extra effort should be made to detect such a feature during pathologic examination, and additional treatment and close follow-up should be considered for patients with such pathologic findings. References 1. Klan R, Loy V, Huland H: Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol, 146: , Herr HW: The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol, 162: 74-76, Paulson DF: Critical review of radical cystectomy and indicators of prognosis. Semin Urol, 11: , Amling CL, Thrasher JB, Frazier HA, Dodge RK, Robertson JE, Paulson DF: Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol, 151: 31-35, Soloway MS, Lopez AE, Patel J, Lu Y: Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy. Cancer, 73: , Freeman JA, Esrig D, Stein JP, Simoneau AR, Skinner EC, Chen SC, Groshen S, Lieskovsky G, Boyd SD, Skinner DG: Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer, 76: , Epstein JI, Amin MB, Reuter VR, Mostofi FK: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol, 22: , Reuter VE, Epstein JI, Amin MB, Mostofi FK: The WHO/ISUP Consensus Classification of Urothelial (Transitional Cell) Neoplasms : continued discussion. Hum Pathol, 30: , Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53: , Cox DR: Regression models and life-tables. J R Stat Soc, 34: , Chang SS, Hassan JM, Cookson MS, Wells N, Smith JA Jr: Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol, 170: , Coblentz TR, Mills SE, Theodorescu D: Impact of second opinion pathology in the definitive management of patients with bladder carcinoma. Cancer, 91: , Richie JP, Skinner DG, Kaufman JJ: Radical cystectomy for carcinoma of the bladder: 16 years of experience. J Urol, 113: , Dalbagni G, Herr HW, Reuter VE: Impact of the second transurethral resection on the staging of T1 bladder cancer. Urology, 60: , Schwaibold HE, Sivalingam S, May F, Hartung R: The value of a second transurethral resection for T1 bladder cancer. BJU Int, 97: , Divrik T, Yildirim U, Eroglu AS, Zorlu F, Ozen H: Is a second tranurethral resection necessary for newly diagnosed pt1 bladder cancer? J Urol, 175: , Stein JP: Indications for early cystectomy. Urology, 62: , Fossa SD, Reitan JB, Ous S, Odegaard A, Loeb M: Prediction of tumour progression in superficial bladder carcinoma. Eur Urol, 11: 1-5, Leissner J, Koeppen C, Wolf HK: Prognostic significance of vascular and perineural invasion in urothelial bladder cancer treated with radical cystectomy. J Urol, 169: , Platz CE, Cohen MB, Jones MP, Olson DB, Lynch CF: Is microstaging of early invasive cancer of the urinary bladder possible or useful? Mod Pathol, 9: , Bassi P, Ferrante GD, Piazza N, Spinadin R, Carando R, Pappagallo G, Pagano F: Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol, 161: , Hara S, Miyake H, Fujisawa M, Okada H, Arakawa S, Kamidono S, Hara I: Prognostic variables in patients who have undergone radical cystectomy for transitional cell carcinoma of the bladder. Jpn J Clin Oncol, 31: , 2001.

Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy

Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Jpn J Clin Oncol 2002;32(11)461 465 Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Takashi Saika, Tomoyasu Tsushima, Yasutomo Nasu, Ryoji Arata,

More information

The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer

The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer Hiroki Ide, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Takashi Ohigashi, Jun Nakashima and Mototsugu

More information

models; Kaplan meier curves were also extrapolated for each cohort to compare disease specific and overall survival patterns.

models; Kaplan meier curves were also extrapolated for each cohort to compare disease specific and overall survival patterns. ; 21 Urological Oncology MUSCULARIS PROPRIA AND UPSTAGING OF ct1 BLADDER CANCER BADALATO ET AL. BJUI Does the presence of muscularis propria on transurethral resection of bladder tumour specimens affect

More information

Optimal Timing of Radical Cystectomy for Patients with Invasive Transitional Cell Carcinoma of the Bladder

Optimal Timing of Radical Cystectomy for Patients with Invasive Transitional Cell Carcinoma of the Bladder Jpn J Clin Oncol 2002;32(1)14 18 Optimal Timing of Radical Cystectomy for Patients with Invasive Transitional Cell Carcinoma of the Bladder Isao Hara, Hideaki Miyake, Shoji Hara, Akinobu Gotoh, Hiroshi

More information

Ivyspring International Publisher. Introduction. Journal of Cancer 2017, Vol. 8. Abstract

Ivyspring International Publisher. Introduction. Journal of Cancer 2017, Vol. 8. Abstract 2885 Ivyspring International Publisher Research Paper Journal of Cancer 2017; 8(15): 2885-2891. doi: 10.7150/jca.20003 Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) After Initial TUR-BT:

More information

Radical Cystectomy Often Too Late? Yes, But...

Radical Cystectomy Often Too Late? Yes, But... european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer

More information

Urological Oncology. Dae Hyeon Kwon, Phil Hyun Song, Hyun Tae Kim.

Urological Oncology. Dae Hyeon Kwon, Phil Hyun Song, Hyun Tae Kim. www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.7.457 Urological Oncology Multivariate Analysis of the Prognostic Significance of Resection Weight after Transurethral Resection of Bladder Tumor

More information

Original Article APMC-276

Original Article APMC-276 Original Article APMC-276 The Clinical Value of Immediate Second Transurethral Resection in Patients with High Grade Non-Muscle Inasive Bladder Cancer (HG-NMIBC) Syed Saleem Abbas Jafri, Zafar Iqbal Khan

More information

Clinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer

Clinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer International Journal of Urology (2011) 18, 439 443 doi: 10.1111/j.1442-2042.2011.02766.x Original Article: Clinical Investigationiju_2766 439..443 Clinical significance of immediate urine cytology after

More information

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction

More information

Radical cystectomy for bladder cancer: oncologic outcome in 271 Chinese patients

Radical cystectomy for bladder cancer: oncologic outcome in 271 Chinese patients Original Article : oncologic outcome in 271 Chinese patients Zhi-Ling Zhang, Pei Dong, Yong-Hong Li, Zhuo-Wei Liu, Kai Yao, Hui Han, Zi-Ke Qin and Fang-Jian Zhou Abstract Few large scale studies have reported

More information

The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell Carcinoma

The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell Carcinoma Ivyspring International Publisher Research Paper 686 Journal of Cancer 2013; 4(8): 686-690. doi: 10.7150/jca.7326 The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell

More information

Second transurethral resection against Ta high grade tumor:residual location and predictive factor. A single center, retrospective study

Second transurethral resection against Ta high grade tumor:residual location and predictive factor. A single center, retrospective study Japanese Journal of Endourology(2018)31:108-112 Original Article CJapanese Society of Endourology 2018 Tetsuya Shindo Naotaka Nishiyama Naoya Masumori Second transurethral resection against Ta high grade

More information

Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience

Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience Fumimasa Fukuta, Naoya Masumori *, Ichiya Honma, Masatoshi Muto, Koji Ichihara, Hiroshi Kitamura

More information

Mixed low and high grade non muscle invasive bladder cancer: a histological subtype with favorable outcome

Mixed low and high grade non muscle invasive bladder cancer: a histological subtype with favorable outcome DOI 10.1007/s00345-014-1383-5 Original Article Mixed low and high grade non muscle invasive bladder cancer: a histological subtype with favorable outcome Tina Schubert Matthew R. Danzig Srinath Kotamarti

More information

Case Presentation 58 year old male with recent history of hematuria, for which he underwent cystoscopy. A 1.5 cm papillary tumor was found in the left lateral wall of the bladder. Pictures of case Case

More information

Koji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto

Koji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto Int J Clin Oncol (2013) 18:75 80 DOI 10.1007/s10147-011-0346-8 ORIGINAL ARTICLE Transurethral prostate biopsy before radical cystectomy remains clinically relevant for decision-making on urethrectomy in

More information

Controversies in the management of Non-muscle invasive bladder cancer

Controversies in the management of Non-muscle invasive bladder cancer Controversies in the management of Non-muscle invasive bladder cancer Sia Daneshmand, MD Associate Professor of Urology (Clinical Scholar) Director of Urologic Oncology Director of Clinical Research Urologic

More information

The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis

The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis Bladder Cancer 2 (2016) 273 278 DOI 10.3233/BLC-160048 IOS Press Research Report 273 The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis Ashish

More information

Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D.

Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.

More information

Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy

Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy Jacob T. Ark*, Kirk A. Keegan*, Daniel A. Barocas*, Todd M. Morgan*, Matthew J.

More information

Non Muscle Invasive Bladder Cancer. Primary and Recurrent TCC 4/10/2010. Two major consequences: Strategies: High-Risk NMI TCC

Non Muscle Invasive Bladder Cancer. Primary and Recurrent TCC 4/10/2010. Two major consequences: Strategies: High-Risk NMI TCC Intravesical Therapy 2010-When, with What, When to Stop Friday, April 9, 2010 Ralph de VereWhite, MD Director, UC Davis Cancer Center Associate Dean for Cancer Programs Professor, Department of Urolgoy

More information

The Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary Study

The Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary Study The Journal of International Medical Research 2009; 37: 1823 1830 The Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary

More information

The Clinical Impact of the Classification of Carcinoma In Situ on Tumor Recurrence and their Clinical Course in Patients with Bladder Tumor

The Clinical Impact of the Classification of Carcinoma In Situ on Tumor Recurrence and their Clinical Course in Patients with Bladder Tumor Original Article Japanese Journal of Clinical Oncology Advance Access published December 17, 2010 Jpn J Clin Oncol 2010 doi:10.1093/jjco/hyq228 The Clinical Impact of the Classification of Carcinoma In

More information

Prognosis of Muscle-Invasive Bladder Cancer: Difference between Primary and ProgressiveTumours and Implications fortherapy

Prognosis of Muscle-Invasive Bladder Cancer: Difference between Primary and ProgressiveTumours and Implications fortherapy European Urology European Urology 45 (2004) 292 296 Prognosis of Muscle-Invasive Bladder Cancer: Difference between Primary and ProgressiveTumours and Implications fortherapy Barthold Ph. Schrier a, Maarten

More information

Bone Metastases in Muscle-Invasive Bladder Cancer

Bone Metastases in Muscle-Invasive Bladder Cancer Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer

More information

Peritoneal Involvement in Stage II Colon Cancer

Peritoneal Involvement in Stage II Colon Cancer Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.

More information

A Fourteen-Year Review of Radical Cystectomy for Transitional Cell Carcinoma Demonstrating the Usefulness of the Concept of Lymph Node Density

A Fourteen-Year Review of Radical Cystectomy for Transitional Cell Carcinoma Demonstrating the Usefulness of the Concept of Lymph Node Density Clinical Urology TCC of the Bladder and Lymph Node Density International Braz J Urol Vol. 32 (5): 536-549, September - October, 2006 A Fourteen-Year Review of Radical Cystectomy for Transitional Cell Carcinoma

More information

Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening progression

Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening progression Kobayashi et al. BMC Urology 2014, 14:5 RESEARCH ARTICLE Open Access Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening

More information

ORIGINAL ARTICLE. Ja Hyeon Ku 1, Kyung Chul Moon 2, Sung Yong Cho 1, Cheol Kwak 1 and Hyeon Hoe Kim 1

ORIGINAL ARTICLE. Ja Hyeon Ku 1, Kyung Chul Moon 2, Sung Yong Cho 1, Cheol Kwak 1 and Hyeon Hoe Kim 1 (2011) 13, 248 253 ß 2011 AJA, SIMM & SJTU. All rights reserved 1008-682X/11 $32.00 www.nature.com/aja ORIGINAL ARTICLE Serum prostate-specific antigen value adjusted for non-cancerous prostate tissue

More information

Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience

Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience International Scholarly Research Notices, Article ID 702653, 6 pages http://dx.doi.org/10.1155/2014/702653 Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer

More information

The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.

The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy. 30 th Congress of the European Society of Pathology Tuesday, September 11, 2018 The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.

More information

BJUI. Invasive T1 bladder cancer: indications and rationale for radical cystectomy

BJUI. Invasive T1 bladder cancer: indications and rationale for radical cystectomy 2008 The Authors; Journal compilation 2008 BJU International Mini-review Article INVASIVE T1 BLADDER CANCER: INDICATIONS AND RATIONALE FOR RADICAL CYSTECTOMY STEIN and PENSON BJUI BJU INTERNATIONAL Invasive

More information

A Personal History NIH CWRU U of TN U of Miami Animal Model for Bladder Cancer Carcinogen induced FANFT Three Models Primary tumors individual tumors, simulates clinical scenario of locally advanced cancer

More information

The clinical significance of a second transurethral resection for T1 high-grade bladder cancer: Results of a prospective study

The clinical significance of a second transurethral resection for T1 high-grade bladder cancer: Results of a prospective study Original Article - Urological Oncology Korean J Urol 2015;56:429-434. pissn 2005-6737 eissn 2005-6745 The clinical significance of a second transurethral resection for T1 high-grade bladder cancer: Results

More information

Lymphovascular invasion predicts poor prognosis in high-grade pt1 bladder cancer patients who underwent transurethral resection in one piece

Lymphovascular invasion predicts poor prognosis in high-grade pt1 bladder cancer patients who underwent transurethral resection in one piece JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(5) 447 452 doi: 10.1093/jjco/hyx012 Advance Access Publication Date: 10 February 2017 Original Article Original

More information

Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors

Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors ORIGINAL ARTICLE Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors Chen-Hsun Ho, 1,2 Chao-Yuan Huang, 1 Wei-Chou Lin, 3 Shih-Chieh Chueh, 1 Yeong-Shiau

More information

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER 10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg

More information

Prognostic value of visceral pleura invasion in non-small cell lung cancer q

Prognostic value of visceral pleura invasion in non-small cell lung cancer q European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung

More information

Lymphadenectomy with Cystectomy: Is It Necessary

Lymphadenectomy with Cystectomy: Is It Necessary European Urology European Urology 46 (2004) 457 461 Lymphadenectomy with Cystectomy: Is It Necessary and What Is Its Extent? Mohamed A. Ghoneim *, Hassan Abol-Enein Urology & Nephrology Center, Gomhouria

More information

Pathologic Assessment of Invasion in TUR Specimens. A. Lopez-Beltran. T1 (ct1)

Pathologic Assessment of Invasion in TUR Specimens. A. Lopez-Beltran. T1 (ct1) Pathologic Assessment of Invasion in TUR Specimens A. Lopez-Beltran T1 (ct1) 1 Prognostic factors for progression/invasive disease Ta,T1,CIS- NMIBC :TNM 2017 ESSENTIAL: Grade T stage CIS Number of lesions

More information

Staging and Grading Last Updated Friday, 14 November 2008

Staging and Grading Last Updated Friday, 14 November 2008 Staging and Grading Last Updated Friday, 14 November 2008 There is a staging graph below Blood in the urine is the most common indication that something is wrong. Often one will experience pain or difficulty

More information

Role of Re-Resection in Non Muscle-Invasive Bladder Cancer

Role of Re-Resection in Non Muscle-Invasive Bladder Cancer Review Special Issue: Bladder Cancer TheScientificWorldJOURNAL (2011) 11, 283 288 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2011.29 Role of Re-Resection in Non Muscle-Invasive Bladder Cancer Harry W.

More information

Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder

Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder Original Article p53 AS A PROGNOSTIC MARKER IN BLADDER CANCER DALBAGNI et al. There have been several published reports that p53 is a useful prognostic marker for progression and survival in bladder cancer.

More information

1. Introduction. 2. Methods. high-risk NMIBC in men with and without a prior history of RT for PC.

1. Introduction. 2. Methods. high-risk NMIBC in men with and without a prior history of RT for PC. ISRN Urology Volume 2013, Article ID 405064, 5 pages http://dx.doi.org/10.1155/2013/405064 Research Article Radical Cystectomy after BCG Immunotherapy for High-Risk Nonmuscle-Invasive Bladder Cancer in

More information

Does the Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Improve Survival in Bladder Cancer?

Does the Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Improve Survival in Bladder Cancer? Does the Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Improve Survival in Bladder Cancer? Authors: Roderick Clark, 1 Kevin Wong, 2 Stacy Fan, 2 Joseph Chin, 1,3 Jonathan

More information

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/96833

More information

Harry W. Herr and S. Machele Donat Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Harry W. Herr and S. Machele Donat Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA . JOURNAL COMPILATION 2008 BJU INTERNATIONAL Miscellaneous QUALITY CONTROL IN TRANSURETHRAL RESECTION OF BLADDER TUMOURS HERR and DONAT BJUI BJU INTERNATIONAL Quality control in transurethral resection

More information

Maintenance Therapy with Intravesical Bacillus Calmette Guérin in Patients with Intermediate- or High-risk Non-muscle-invasive

Maintenance Therapy with Intravesical Bacillus Calmette Guérin in Patients with Intermediate- or High-risk Non-muscle-invasive Jpn J Clin Oncol 2013;43(3)305 313 doi:10.1093/jjco/hys225 Advance Access Publication 9 January 2013 Maintenance Therapy with Intravesical Bacillus Calmette Guérin in Patients with Intermediate- or High-risk

More information

2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections

2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections european urology supplements 8 (2009) 453 457 available at www.sciencedirect.com journal homepage: www.europeanurology.com 2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms:

More information

RESEARCH ARTICLE. Ali Koyuncuer. Abstract. Introduction. Materials and Methods

RESEARCH ARTICLE. Ali Koyuncuer. Abstract. Introduction. Materials and Methods RESEARCH ARTICLE Histopathologic Evolution of Urothelial Carcinoma Recurrence in Transurethral Resection of the Urinary Bladder:35 Consecutive Cases And Literature Review Abstract Background: Urothelial

More information

Large blocks in prostate and bladder pathology

Large blocks in prostate and bladder pathology Large blocks in prostate and bladder pathology Farkas Sükösd Department of Pathology, University of Szeged The history of the large block technique in radical prostatectomy and cystectomy The first large

More information

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction

More information

Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection

Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection Dr. Michael Co Division of Breast Surgery Queen Mary Hospital The University of Hong Kong Conflicts

More information

Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience

Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,

More information

Issues in the Management of High Risk Superficial Bladder Cancer

Issues in the Management of High Risk Superficial Bladder Cancer Issues in the Management of High Risk Superficial Bladder Cancer MICHAEL A.S. JEWETT DIVISION OF UROLOGY, DEPARTMENT OF SURGICAL ONCOLOGY, PRINCESS MARGARET HOSPITAL & THE UNIVERSITY OF TORONTO 1 Carcinoma

More information

Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure

Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure Itay A. Sternberg, Guido Dalbagni,* Ling Y. Chen, Sherri M. Donat, Bernard H.

More information

Survival of Patients with Transitional Cell Carcinoma of the Urinary Bladder in Indonesia: A Single Institution Review

Survival of Patients with Transitional Cell Carcinoma of the Urinary Bladder in Indonesia: A Single Institution Review RESEARCH COMMUNICATION Survival of Patients with Transitional Cell Carcinoma of the Urinary Bladder in Indonesia: A Single Institution Review Wempy Supit, Chaidir A Mochtar *, Marto Sugiono, Rainy Umbas

More information

Reviewing Immunotherapy for Bladder Carcinoma In Situ

Reviewing Immunotherapy for Bladder Carcinoma In Situ Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy

More information

Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea. 2

Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea. 2 UROLOGICAL ONCOLOGY Effects of Previous or Synchronous Non-Muscle Invasive Bladder Cancer on Clinical Results after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multi-Institutional

More information

Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital

Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital E-Da Medical Journal 20;():-5 Original Article Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital Wei-Ting Kuo, I-Wei Chang2, Kevin Lu, Hua-Pin Wang, Tsan-Jung u, Victor C.

More information

How Many Diseases in Carcinoma in situ?

How Many Diseases in Carcinoma in situ? How Many Diseases in Carcinoma in situ? Eva Compérat La Pitié Salpêtrière Assistance Publique Université Pierre et Marie Curie, Paris VI Carcinogenesis of Bladder Cancer (BC) BC is a panurothelial disease

More information

Radiochemotherapy after Transurethral Resection is an Effective Treatment Method in T1G3 Bladder Cancer

Radiochemotherapy after Transurethral Resection is an Effective Treatment Method in T1G3 Bladder Cancer Radiochemotherapy after Transurethral Resection is an Effective Treatment Method in T1G3 Bladder Cancer Z. AKÇETIN 1, J. TODOROV 1, E. TÜZEL 1, D.G. ENGEHAUSEN 1, F.S. KRAUSE 1, R. SAUER 2, K.M. SCHROTT

More information

Haematuria and Bladder Cancer

Haematuria and Bladder Cancer Haematuria and Bladder Cancer Dr Pardeep Kumar Consultant Urological Surgeon Haematuria 3 Haematuria Macroscopic vs Microscopic Painful vs Painless Concurrent abdo pain/urinary symptoms Previous testing?

More information

Are Prostate Carcinoma Clinical Stages T1c and T2 Similar?

Are Prostate Carcinoma Clinical Stages T1c and T2 Similar? Clinical Urology Are Clinical Stages T1c and T2 Similar? International Braz J Urol Vol. 32 (2): 165-171, March - April, 2006 Are Prostate Carcinoma Clinical Stages T1c and T2 Similar? Athanase Billis,

More information

Disease Speci c Survival as Endpoint of Outcome for Bladder Cancer Patients Following Radical Cystectomy

Disease Speci c Survival as Endpoint of Outcome for Bladder Cancer Patients Following Radical Cystectomy European Urology European Urology 41 2002) 440±448 Disease Speci c Survival as Endpoint of Outcome for Bladder Cancer Patients Following Radical Cystectomy JuÈrgen E. Gschwend a,b,*, Philipp Dahm c, WilliamR.

More information

Analysis of the outcome of young age tongue squamous cell carcinoma

Analysis of the outcome of young age tongue squamous cell carcinoma Jeon et al. Maxillofacial Plastic and Reconstructive Surgery (2017) 39:41 DOI 10.1186/s40902-017-0139-8 Maxillofacial Plastic and Reconstructive Surgery RESEARCH Open Access Analysis of the outcome of

More information

Early radical cystectomy in NMIBC Marko Babjuk

Early radical cystectomy in NMIBC Marko Babjuk Early radical cystectomy in NMIBC Marko Babjuk Dept. of Urology, 2nd Faculty of Medicine, Hospital Motol, Praha, Czech Republic We Are The European Association of Urology We Are Urologists, residents,

More information

Comparative Outcomes of Primary, Recurrent, and Progressive High-risk Non muscle-invasive Bladder Cancer

Comparative Outcomes of Primary, Recurrent, and Progressive High-risk Non muscle-invasive Bladder Cancer EUROPEAN UROLOGY 63 (2013) 145 154 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Urothelial Cancer Editorial by J. Alfred Witjes on pp. 155 157 of this

More information

Risk groups in bladder cancer patients treated with radical cystectomy

Risk groups in bladder cancer patients treated with radical cystectomy ORIGINAL ARTICLE Vol. 41 (1): 30-39, January - February, 2015 doi: 10.1590/S1677-5538.IBJU.2015.01.06 Risk groups in bladder cancer patients treated with radical cystectomy Eva Mallen 1, Pedro Gil 2, Maria

More information

Conclusions. Keywords

Conclusions. Keywords Outcomes of radical cystectomy with extended lymphadenectomy alone in patients with lymph node-positive bladder cancer who are unfit for or who decline adjuvant chemotherapy Pascal Zehnder*, Urs E. Studer,

More information

A Review of Outcomes for Stage Ta Bladder Tumors

A Review of Outcomes for Stage Ta Bladder Tumors AJCP /ORIGINAL ARTICLE A Review of Outcomes for Stage Ta Bladder Tumors Robin T. Vollmer, MD From the VA and Duke University Medical Centers, Durham, NC. Key Words: Urothelial tumors; Tumor grade; Outcomes;

More information

Bladder Cancer Guidelines

Bladder Cancer Guidelines Bladder Cancer Guidelines Agreed by Urology CSG: October 2011 Review Date: September 2013 Bladder Cancer 1. Referral Guidelines The following patients should be considered as potentially having bladder

More information

Cytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis

Cytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis https://doi.org/10.1186/s13104-018-3319-4 BMC Research Notes RESEARCH NOTE Open Access Cytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis Atif Ali

More information

Oncologic Outcomes of Patients With Gleason Score 7 and Tertiary Gleason Pattern 5 After Radical Prostatectomy

Oncologic Outcomes of Patients With Gleason Score 7 and Tertiary Gleason Pattern 5 After Radical Prostatectomy www.kjurology.org http://dx.doi.org/10.4111/kju.2013.54.9.587 Urological Oncology Oncologic Outcomes of Patients With Gleason Score 7 and Tertiary Gleason Pattern 5 After Radical Prostatectomy Yi-Hsueh

More information

Impact of Histopathological Variant on the Outcome of Patients Treated by Radical Cystectomy

Impact of Histopathological Variant on the Outcome of Patients Treated by Radical Cystectomy www.kjurology.org http://dx.doi.org/./kju... Original Article Urological Oncology http://crossmark.crossref.org/dialog/?doi=./kju...&domain=pdf&date_stamp= Impact of Histopathological Variant on the Outcome

More information

Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer

Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer Patrick A. Cockerill, John J. Knoedler, Igor Frank, Robert Tarrell and Robert

More information

Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05

Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05 Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan

More information

Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer

Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer The new england journal of medicine original article Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer H. Barton Grossman, M.D., Ronald B. Natale,

More information

Upper urinary tract urothelial carcinomas (UTUC)

Upper urinary tract urothelial carcinomas (UTUC) Prognostic Role of Lymphovascular Invasion in Patients with Urothelial Carcinoma of the Upper Urinary Tract Manel Mellouli 1 *, Slim Charfi 1, Walid Smaoui 2, Rim Kallel 1, Abdelmajid Khabir 1, Mehdi Bouacida

More information

Update on bladder neoplasia: 2016 WHO classification and recent developments within the pathologic, molecular & clinical domains of the disease

Update on bladder neoplasia: 2016 WHO classification and recent developments within the pathologic, molecular & clinical domains of the disease Update on bladder neoplasia: 2016 WHO classification and recent developments within the pathologic, molecular & clinical domains of the disease Biology of urothelial tumorigenesis: insights from genetically

More information

Preoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy

Preoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical

More information

Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer

Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group

More information

Citation International journal of urology (2. Right which has been published in final f

Citation International journal of urology (2.  Right which has been published in final f Title Novel constant-pressure irrigation of renal pelvic tumors after ipsila Nakamura, Kenji; Terada, Naoki; Sug Author(s) Toshinori; Matsui, Yoshiyuki; Imamu Kazutoshi; Kamba, Tomomi; Yoshimura Citation

More information

Comparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population

Comparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population DOI 10.1007/s10147-015-0812-9 ORIGINAL ARTICLE Comparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population Yasunobu

More information

Pathology review impacts clinical management of patients with T1 T2 bladder cancer

Pathology review impacts clinical management of patients with T1 T2 bladder cancer Original research Pathology review impacts clinical management of patients with T1 T2 bladder cancer Samer L. Traboulsi, MD 1 ; Fadi Brimo, MD, FRCP(C) 2 ; Yutong Yang, MD 2 ; Chelsea Maedler, MD 2 ; Noémie

More information

Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity

Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity EUROPEAN UROLOGY 61 (2012) 1025 1030 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy:

More information

Carcinoma of the Urinary Bladder Histopathology

Carcinoma of the Urinary Bladder Histopathology Carcinoma of the Urinary Bladder Histopathology Reporting Proforma (Radical & Partial Cystectomy, Cystoprostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family

More information

Frequency and predictors of recurrence of bladder tumour on first check cystoscopy a tertiary care hospital experience

Frequency and predictors of recurrence of bladder tumour on first check cystoscopy a tertiary care hospital experience 2nd Annual Surgical Meeting 2016 S-125 UROLOGY ORIGINAL ARTICLE Frequency and predictors of recurrence of bladder tumour on first check cystoscopy a tertiary care hospital experience Muhammad Farhan, Syed

More information

Is Hepatic Resection Needed in the Patients with Peritoneal Side T2 Gallbladder Cancer?

Is Hepatic Resection Needed in the Patients with Peritoneal Side T2 Gallbladder Cancer? Is Hepatic Resection Needed in the Patients with Peritoneal Side T2 Gallbladder Cancer? Lee H, Park JY, Youn S, Kwon W, Heo JS, Choi SH, Choi DW Department of Surgery, Samsung Medical Center Sungkyunkwan

More information

NMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland

NMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland NMIBC Piotr Jarzemski Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland 71 year old male patient was admitted to the Department of Urology First TURBT - 2 months prior to the hospitalisation.

More information

Results. Objectives. Patients and methods. Conclusions

Results. Objectives. Patients and methods. Conclusions The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/grade 3 bladder cancer treated with bacille Calmette Guerin Paolo Gontero 1, Richard

More information

ESD for EGC with undifferentiated histology

ESD for EGC with undifferentiated histology ESD for EGC with undifferentiated histology Jun Haeng Lee, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Biopsy: M/D adenocarcinoma ESD: SRC >>

More information

Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma

Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma Anatomic Pathology / CYTOKERATINS 7 AND 20 IN PROSTATE AND BLADDER CARCINOMAS Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma Nader H. Bassily,

More information

BJUI. Principal component analysis based pre-cystectomy model to predict pathological stage in patients with clinical organ-confined bladder cancer

BJUI. Principal component analysis based pre-cystectomy model to predict pathological stage in patients with clinical organ-confined bladder cancer BJUI BJU INTERNATIONAL Principal component analysis based pre-cystectomy model to predict pathological stage in patients with clinical organ-confined bladder cancer Hamed Ahmadi, Anirban P. Mitra *, George

More information

Non-muscle invasive bladder cancer: Are epicrises the Bermuda Triangle of information transfer?

Non-muscle invasive bladder cancer: Are epicrises the Bermuda Triangle of information transfer? 245 O R I G I N A L P A P E R UROLOGICAL ONCOLOGY Non-muscle invasive bladder cancer: Are epicrises the Bermuda Triangle of information transfer? Steffen Lebentrau 1, Matthias May 2, Anne-Kathrin Wick

More information

Multiple factor analysis of metachronous upper urinary tract transitional cell carcinoma after radical cystectomy

Multiple factor analysis of metachronous upper urinary tract transitional cell carcinoma after radical cystectomy Brazilian Journal of Medical and Biological Research (2007) 40: 979-984 Predictive factors after radical cystectomy ISSN 0100-879X 979 Multiple factor analysis of metachronous upper urinary tract transitional

More information

Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival

Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae Joon Kim, MD, Seong Yong Park, MD, Kil Dong Kim,

More information